Literature DB >> 3016607

Present status and future role of surgery for malignant supratentorial gliomas.

J Garfield.   

Abstract

Despite a voluminous literature it remains difficult to draw conclusions about the precise place of surgery in the management of patients with supratentorial malignant gliomas (anaplastic astrocytoma and glioblastoma multiforme). If the beneficial effects of radiotherapy are discounted, excisional surgery itself probably achieves no more than a survival of 4 to 6 months. The apparently beneficial effects of excisional surgery are related more to radiotherapy than to the surgery itself, beyond the immediate relief of raised intracranial pressure. So far in EORTC Brain Tumour Group studies there is no evidence of any significant beneficial effect from chemotherapy after excisional surgery. Whatever adjuvant methods of therapy are developed in the future, it will remain necessary to separate the effects of surgery from those of the adjuvant therapy. There will therefore be a continuing need for a basic human model whereby the effects of surgery can be clarified, and for that reason it will always be necessary to have a treatment arm without excisional surgery. A format is proposed taking into account favorable prognostic factors such as age and Karnofsky index, which should provide a basis for critical evaluation. The difficulties of adhering to the format are stressed.

Entities:  

Mesh:

Year:  1986        PMID: 3016607     DOI: 10.1007/bf01743049

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  10 in total

1.  TREATMENT OF MALIGNANT GLIOMATA.

Authors:  E HITCHCOCK; R SATO
Journal:  J Neurosurg       Date:  1964-06       Impact factor: 5.115

2.  Glioblastoma multiforme: a clinical survey.

Authors:  J G ROTH; A R ELVIDGE
Journal:  J Neurosurg       Date:  1960-07       Impact factor: 5.115

3.  Glioblastoma multiforme; review of 219 cases with regard to natural history, pathology, diagnostic methods, and treatment.

Authors:  S A FRANKEL; W J GERMAN
Journal:  J Neurosurg       Date:  1958-09       Impact factor: 5.115

4.  A study of 211 patients with verified glioblastoma multiforme.

Authors:  L DAVIS; J MARTIN
Journal:  J Neurosurg       Date:  1949-01       Impact factor: 5.115

5.  Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma--final evaluation. E.O.R.T.C. Brain Tumor Group.

Authors: 
Journal:  Eur J Cancer       Date:  1978-08       Impact factor: 9.162

6.  Postoperative intracavitary chemotherapy of malignant gliomas. A preliminary study using methotrexate.

Authors:  J Garfield; A D Dayan
Journal:  J Neurosurg       Date:  1973-09       Impact factor: 5.115

7.  The treatment of glioblastoma multiforme of the brain.

Authors:  R Jelsma; P C Bucy
Journal:  J Neurosurg       Date:  1967-11       Impact factor: 5.115

8.  The relative significance of factors affecting postoperative survival in astrocytomas, grades 3 and 4.

Authors:  B Weir
Journal:  J Neurosurg       Date:  1973-04       Impact factor: 5.115

9.  Survival in glioblastoma: historical perspective.

Authors:  M Salcman
Journal:  Neurosurgery       Date:  1980-11       Impact factor: 4.654

10.  Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group.

Authors: 
Journal:  J Neurosurg       Date:  1981-07       Impact factor: 5.115

  10 in total
  2 in total

1.  Stereological estimates of nuclear volume and other quantitative variables in supratentorial brain tumors. Practical technique and use in prognostic evaluation.

Authors:  F B Sørensen; H Braendgaard; A O Chistiansen; M Bojsen-Møller; E Reske-Nielsen
Journal:  J Neurooncol       Date:  1991-06       Impact factor: 4.130

2.  The effects of local and systemic interferon beta (Fiblaferon) on supratentorial malignant cerebral glioma--a phase II study.

Authors:  K R von Wild; T H Knocke
Journal:  Neurosurg Rev       Date:  1991       Impact factor: 3.042

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.